Sarcoma is one indication for VEGF/VEGFR targeted therapy, based on its effects on angiogenesis and the observation that overexpression of VEGFRs, particularly VEGFR-2, and is significantly associated with low survival rates in patients with sarcomas [16, 20–23]. This evidence concerns the gene KDR and sarcoma.